This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Igietseme, J. U.
Right arrow Articles by Black, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igietseme, J. U.
Right arrow Articles by Black, C. M.

 Previous Article  |  Next Article 

Infection and Immunity, September 1998, p. 4030-4035, Vol. 66, No. 9
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Route of Infection That Induces a High Intensity of Gamma Interferon-Secreting T Cells in the Genital Tract Produces Optimal Protection against Chlamydia trachomatis Infection in Mice

Joseph U. Igietseme,1,* Ijindah M. Uriri,1 Shantha N. Kumar,1 Godwin A. Ananaba,2 Omegbhai O. Ojior,1 Inua A. Momodu,1 Debra H. Candal,3 and Carolyn M. Black3

Department of Microbiology and Immunology, Morehouse School of Medicine, Atlanta, Georgia 303101; Department of Biology, Spelman College, Atlanta, Georgia 303142; and National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303333

Received 19 March 1998/Returned for modification 5 May 1998/Accepted 10 June 1998

The induction of local T helper type 1 (Th1)-mediated cellular immunity is crucial for resistance of mice to genital infection by the obligate intracellular bacterium Chlamydia trachomatis. We tested the hypothesis that the route of immunization that elicits relatively high numbers of chlamydia-specific, gamma interferon (IFN-gamma )-secreting T lymphocytes (ISTLs) in the genital tract would induce optimal protective immunity against reinfection. Female BALB/c mice were infected intravaginally (i.v.), intranasally (i.n.), orally (p.o.), or subcutaneously (s.c.) with C. trachomatis. At days 7, 14, 21, and 28 postinfection, T cells isolated from the genital tract tissues were restimulated with chlamydial antigen in vitro, and the amounts of IFN-gamma induced were measured by a sandwiched enzyme-linked immunosorbent assay method. At day 7 postinfection, i.n.- and i.v.-immunized mice had high levels of chlamydia-specific ISTLs in their genital tracts (203.58 ± 68.1 and 225.5 ± 12.1 pg/ml, respectively). However, there were no detectable ISTLs in the genital tracts of p.o.- or s.c.-infected mice. When preinfected mice were challenged i.v. 70 days later, animals preexposed by the i.n. route were highly resistant to reinfection, with greatly reduced chlamydial burden, and suffered an attenuated infection that resolved by day 6 postchallenge. Animals preexposed by the i.v. route were modestly protected, whereas p.o. and s.c. groups were indistinguishable in this regard from control mice. The resistance of i.n.-immunized mice (and to some extent the i.v.-exposed mice) to reinfection was associated with early appearance (within 24 h) of high levels of genital ISTLs compared with mice preinfected by other routes. Furthermore, although i.n. and i.v.-immunized mice had comparable levels of chlamydia-specific immunoglobulin A (IgA) antibodies in their vaginal washes, the levels of IgG2a were four- sixfold higher in i.n.-immunized mice than in any of the other groups. The results suggested that immunization routes that foster rapid induction of vigorous genital mucosal cell-mediated immune (CMI) effectors (e.g., IFN-gamma ), the CMI-associated humoral effector, IgG2a, and to some extent secretory IgA produce protective immunity against chlamydial genital infection. Therefore, i.n. immunization is a potential delivery route of choice in the development of a vaccine against Chlamydia.


* Corresponding author. Mailing address: Morehouse School of Medicine, Department of Microbiology and Immunology, 720 Westview Dr., SW, Atlanta, GA 30310. Phone: (404) 752-1596. Fax: (404) 752-1179. E-mail: igietsj{at}msm.edu.


Infection and Immunity, September 1998, p. 4030-4035, Vol. 66, No. 9
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Eickhoff, M., Thalmann, J., Hess, S., Martin, M., Laue, T., Kruppa, J., Brandes, G., Klos, A. (2007). Host Cell Responses to Chlamydia pneumoniae in Gamma Interferon-Induced Persistence Overlap Those of Productive Infection and Are Linked to Genes Involved in Apoptosis, Cell Cycle, and Metabolism. Infect. Immun. 75: 2853-2863 [Abstract] [Full Text]  
  • He, Q., Moore, T. T., Eko, F. O., Lyn, D., Ananaba, G. A., Martin, A., Singh, S., James, L., Stiles, J., Black, C. M., Igietseme, J. U. (2005). Molecular Basis for the Potency of IL-10-Deficient Dendritic Cells as a Highly Efficient APC System for Activating Th1 Response. J. Immunol. 174: 4860-4869 [Abstract] [Full Text]  
  • Eko, F. O., He, Q., Brown, T., McMillan, L., Ifere, G. O., Ananaba, G. A., Lyn, D., Lubitz, W., Kellar, K. L., Black, C. M., Igietseme, J. U. (2004). A Novel Recombinant Multisubunit Vaccine against Chlamydia. J. Immunol. 173: 3375-3382 [Abstract] [Full Text]  
  • Darville, T., O'Neill, J. M., Andrews, C. W. Jr., Nagarajan, U. M., Stahl, L., Ojcius, D. M. (2003). Toll-Like Receptor-2, but Not Toll-Like Receptor-4, Is Essential for Development of Oviduct Pathology in Chlamydial Genital Tract Infection. J. Immunol. 171: 6187-6197 [Abstract] [Full Text]  
  • Csencsits, K. L., Pascual, D. W. (2002). Absence of L-Selectin Delays Mucosal B Cell Responses in Nonintestinal Effector Tissues. J. Immunol. 169: 5649-5659 [Abstract] [Full Text]  
  • He, Q., Mitchell, A., Morcol, T., Bell, S. J. D. (2002). Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection against Herpes Simplex Virus Type 2. CVI 9: 1021-1024 [Abstract] [Full Text]  
  • Belay, T., Eko, F. O., Ananaba, G. A., Bowers, S., Moore, T., Lyn, D., Igietseme, J. U. (2002). Chemokine and Chemokine Receptor Dynamics during Genital Chlamydial Infection. Infect. Immun. 70: 844-850 [Abstract] [Full Text]  
  • Darville, T., Andrews, C. W. Jr., Sikes, J. D., Fraley, P. L., Braswell, L., Rank, R. G. (2001). Mouse Strain-Dependent Chemokine Regulation of the Genital Tract T Helper Cell Type 1 Immune Response. Infect. Immun. 69: 7419-7424 [Abstract] [Full Text]  
  • Pate, M. S., Hedges, S. R., Sibley, D. A., Russell, M. W., Hook, E. W. III, Mestecky, J. (2001). Urethral Cytokine and Immune Responses in Chlamydia trachomatis-Infected Males. Infect. Immun. 69: 7178-7181 [Abstract] [Full Text]  
  • Morrison, S. G., Morrison, R. P. (2001). Resolution of Secondary Chlamydia trachomatis Genital Tract Infection in Immune Mice with Depletion of Both CD4+ and CD8+ T cells. Infect. Immun. 69: 2643-2649 [Abstract] [Full Text]  
  • Igietseme, J. U., Portis, J. L., Perry, L. L. (2001). Inflammation and Clearance of Chlamydia trachomatis in Enteric and Nonenteric Mucosae. Infect. Immun. 69: 1832-1840 [Abstract] [Full Text]  
  • Igietseme, J. U., Murdin, A. (2000). Induction of Protective Immunity against Chlamydia trachomatis Genital Infection by a Vaccine Based on Major Outer Membrane Protein-Lipophilic Immune Response-Stimulating Complexes. Infect. Immun. 68: 6798-6806 [Abstract] [Full Text]  
  • Hawkins, R. A., Rank, R. G., Kelly, K. A. (2000). Expression of Mucosal Homing Receptor alpha 4beta 7 Is Associated with Enhanced Migration to the Chlamydia-Infected Murine Genital Mucosa In Vivo. Infect. Immun. 68: 5587-5594 [Abstract] [Full Text]  
  • Igietseme, J. U., Ananaba, G. A., Bolier, J., Bowers, S., Moore, T., Belay, T., Eko, F. O., Lyn, D., Black, C. M. (2000). Suppression of Endogenous IL-10 Gene Expression in Dendritic Cells Enhances Antigen Presentation for Specific Th1 Induction: Potential for Cellular Vaccine Development. J. Immunol. 164: 4212-4219 [Abstract] [Full Text]